Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRecruitment status updated to 'No longer looking for participants' and new help sections were added (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention/Treatment heading was updated and the page revision shows v3.6.0.SummaryDifference0.2%

- Check20 days agoChange DetectedThe page’s revision badge shows v3.5.5, replacing the previous v3.5.4. This appears to be a minor, system-level update (software/documentation version) rather than a change to study content or functionality.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision: v3.5.4 replaces the previous v3.5.3 label, signaling a backend or UI update unrelated to study details.SummaryDifference0.0%

- Check48 days agoChange DetectedThe Taiwan location entry was updated from Taoyuan District, Taiwan, 33305 to Taoyuan, Taiwan, 33305, replacing the district designation with the city name while preserving the postal code.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page shows an updated Revision: v3.5.3, replacing v3.5.2, reflecting a software/version update applied to the page.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 on the page. No user-facing content changes are indicated.SummaryDifference0.0%

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.